Revelation Biosciences Inc. Common Stock REVB · Stock Open Revelation Biosciences Inc. Common Stock in new tab
Revelation Biosciences Inc. Common Stock Analysis (REVB)
Is Revelation Biosciences Inc. Common Stock a good investment? Revelation Biosciences Inc. Common Stock (REVB) is currently trading at 0.9763 USD. Market analysts have a consensus price target of 17.75 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.03. This relatively low multiple may signal that Revelation Biosciences Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Revelation Biosciences Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -2.89.
Investor FAQ
Does Revelation Biosciences Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Revelation Biosciences Inc. Common Stock?
Revelation Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 27.03.
Company Profile
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 1, 2023 | 0.03 |
| Jan. 25, 2024 | 0.03 |
| Jan. 28, 2025 | 0.06 |
| July 7, 2025 | 0.33 |
| Jan. 28, 2026 | 1:4 |
Community Discussion